Immix Biopharma
IMMX
18 hedge funds and large institutions have $1.01M invested in Immix Biopharma in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
149% more capital invested
Capital invested by funds: $406K → $1.01M (+$605K)
50% more funds holding
Funds holding: 12 → 18 (+6)
1.01% more ownership
Funds ownership: 2.15% → 3.16% (+1%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$89.6K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$44.8K |
| 3 |
LCM
Lynwood Capital Management
Toronto,
Ontario, Canada
|
+$33.3K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$20K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$16.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$37K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.75K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$309 |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3 |
| 5 |
Morgan Stanley
New York
|
-$3 |
IMMX Hedge Fund Activity: Q4 2022 in Review
18 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Immix Biopharma (IMMX) for Q4 2022, worth a combined $1.01M — up 149% from $406K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IMMX positions and 1 closed out — a net gain of 6 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Murchinson, opening a new position worth an estimated $89.6K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $37K sold.
- 18 institutional investors held Immix Biopharma (IMMX) as of Q4 2022, up from 12 in Q3 2022.
- Funds reported $1.01M of Immix Biopharma stock for Q4 2022, up 149% quarter-over-quarter.
- 7 funds opened new Immix Biopharma positions in Q4 2022 and 1 closed out, a net change of +6 holders.
- The largest Immix Biopharma buyer in Q4 2022 was Murchinson, an estimated $89.6K added.
- The largest Immix Biopharma seller in Q4 2022 was Renaissance Technologies, an estimated $37K sold.
Based on aggregated 13F filings for Q4 2022.